Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FT1 in Short Bowel Syndrome
NCT07704047Phase 2Recruiting
- Sponsor
- Chongqing Peg-Bio Biopharm Co., Ltd.
- Start
- Aug 2026
- Primary completion
- Apr 2027
- Countries
- 1
01
Overview
A Phase 2 trial of notoginsenoside Ft1 in short bowel syndrome (SBS), sponsored by Chongqing Peg-Bio Biopharm Co., Ltd.. Started Aug 2026; status: recruiting.
02
Drugs
notoginsenoside Ft1
03
Conditions
short bowel syndrome (SBS)
Beyond the preview
Go deeper on NCT07704047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07704047.